GT Biopharma Announces Preliminary Clinical Results From Interim Review of Phase 1/2 Clinical Trial of OXS-1550, its Bi-Specific Antibody Drug Conjugate

GT Biopharma Announces Preliminary Clinical Results From Interim Review of Phase 1/2 Clinical Trial of OXS-1550, its Bi-Specific Antibody Drug Conjugate

LOS ANGELES,¬†June 11, 2018¬†/PRNewswire/ — Clinical benefit observed in more than 50% of patients that met evaluation criteria Efficacy signal most pronounced in relapsed/refractory acute lymphocytic leukemia patients (ALL) with clinical benefit in 75% (three of four) of evaluable patients